Article Versions Notes

Kievit H, Muntinghe-Wagenaar MB, Abdulahad WH, Rutgers A, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, van der Leij MJ, Bijzet J, et al. Baseline Blood CD8⁺ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer. Cancers. 2024; 16(14):2592. https://doi.org/10.3390/cancers16142592

Kievit, Hanneke, M. Benthe Muntinghe-Wagenaar, Wayel H. Abdulahad, Abraham Rutgers, Lucie B. M. Hijmering-Kappelle, Birgitta I. Hiddinga, J. Fred Ubbels, Robin Wijsman, Marcel J. van der Leij, Johan Bijzet, and et al. 2024. "Baseline Blood CD8⁺ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer" Cancers 16, no. 14: 2592. https://doi.org/10.3390/cancers16142592

Kievit, H., Muntinghe-Wagenaar, M. B., Abdulahad, W. H., Rutgers, A., Hijmering-Kappelle, L. B. M., Hiddinga, B. I., Ubbels, J. F., Wijsman, R., van der Leij, M. J., Bijzet, J., Groen, H. J. M., Kerstjens, H. A. M., van der Wekken, A. J., Kroesen, B.-J., & Hiltermann, T. J. N. (2024). Baseline Blood CD8⁺ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer. Cancers, 16(14), 2592. https://doi.org/10.3390/cancers16142592